Pinion Investment Advisors LLC Purchases 46 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Pinion Investment Advisors LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 673 shares of the pharmaceutical company’s stock after purchasing an additional 46 shares during the quarter. Pinion Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $326,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $31,000. Truvestments Capital LLC grew its position in shares of Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after purchasing an additional 23 shares in the last quarter. Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. Midwest Capital Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $41,000. Finally, Minot DeBlois Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $44,000. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

VRTX has been the topic of several analyst reports. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wolfe Research lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, May 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $535.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley raised their target price on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Stock Down 1.0%

VRTX stock opened at $455.45 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company’s 50 day moving average is $462.54 and its two-hundred day moving average is $460.13. The stock has a market cap of $116.96 billion, a P/E ratio of -207.02, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $4.76 earnings per share. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.